Hologic Acquires Acessa To Add ProVu Fibroid Treatment
Executive Summary
Hologic has agreed to pay $80m in cash, plus contingent payments for Acessa, a privately held developer of minimally invasive treatments for uterine fibroids.
You may also be interested in...
Hologic Continues Spending Spree With $230M Tuck-In Acquisition Of Biotheranostics
Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.
Hologic Acquires Somatex Medical For $64M To Expand Breast Health Care, European Sales Presence
Hologic’s acquisition of Somatex Medical will expand its biopsy portfolio and direct channel in Germany.
Dealmaking Quarterly Statistics, Q3 2020
During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.